A Machine Learning-Based Approach to Discrimination of Tauopathies Using [
Alzheimer's disease
machine learning
progressive supranuclear palsy
tau PET
tauopathy
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
03
06
2022
received:
07
03
2022
accepted:
10
07
2022
pubmed:
3
9
2022
medline:
16
11
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
We recently developed a positron emission tomography (PET) probe, [ We aimed to establish tau PET pathology indices to characterize PSP and AD using a machine learning approach and test their validity and tracer capabilities. Data were obtained from 50 healthy control subjects, 46 patients with PSP Richardson syndrome, and 37 patients on the AD continuum. Tau PET data from 114 regions of interest were subjected to Elastic Net cross-validation linear classification analysis with a one-versus-the-rest multiclass strategy to obtain a linear function that discriminates diseases by maximizing the area under the receiver operating characteristic curve. We defined PSP- and AD-tau scores for each participant as values of the functions optimized for differentiating PSP (4R) and AD (3R + 4R), respectively, from others. The discriminatory ability of PSP- and AD-tau scores assessed as the area under the receiver operating characteristic curve was 0.98 and 1.00, respectively. PSP-tau scores correlated with the PSP rating scale in patients with PSP, and AD-tau scores correlated with Mini-Mental State Examination scores in healthy control-AD continuum patients. The globus pallidus and amygdala were highlighted as regions with high weight coefficients for determining PSP- and AD-tau scores, respectively. These findings highlight our technology's unbiased capability to identify topologies of 3R + 4R versus 4R tau deposits. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
We recently developed a positron emission tomography (PET) probe, [
OBJECTIVE
We aimed to establish tau PET pathology indices to characterize PSP and AD using a machine learning approach and test their validity and tracer capabilities.
METHODS
Data were obtained from 50 healthy control subjects, 46 patients with PSP Richardson syndrome, and 37 patients on the AD continuum. Tau PET data from 114 regions of interest were subjected to Elastic Net cross-validation linear classification analysis with a one-versus-the-rest multiclass strategy to obtain a linear function that discriminates diseases by maximizing the area under the receiver operating characteristic curve. We defined PSP- and AD-tau scores for each participant as values of the functions optimized for differentiating PSP (4R) and AD (3R + 4R), respectively, from others.
RESULTS
The discriminatory ability of PSP- and AD-tau scores assessed as the area under the receiver operating characteristic curve was 0.98 and 1.00, respectively. PSP-tau scores correlated with the PSP rating scale in patients with PSP, and AD-tau scores correlated with Mini-Mental State Examination scores in healthy control-AD continuum patients. The globus pallidus and amygdala were highlighted as regions with high weight coefficients for determining PSP- and AD-tau scores, respectively.
CONCLUSIONS
These findings highlight our technology's unbiased capability to identify topologies of 3R + 4R versus 4R tau deposits. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 36054492
doi: 10.1002/mds.29173
pmc: PMC9805085
doi:
Substances chimiques
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2236-2246Informations de copyright
© 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Front Neurol. 2019 May 15;10:486
pubmed: 31156534
J Nucl Med. 2020 Jun;61(6):911-919
pubmed: 31712323
J Neurosci. 2007 Oct 10;27(41):10957-68
pubmed: 17928437
Nat Rev Neurosci. 2007 Sep;8(9):663-72
pubmed: 17684513
Brain. 2011 Nov;134(Pt 11):3264-75
pubmed: 21933807
PLoS One. 2013 Jun 18;8(6):e65591
pubmed: 23824159
Acta Neuropathol. 2014 Dec;128(6):755-66
pubmed: 25348064
Mov Disord. 2019 May;34(5):744-754
pubmed: 30892739
Brain Commun. 2020;2(1):fcz046
pubmed: 32051933
Brain Behav. 2019 Oct;9(10):e01363
pubmed: 31483562
JAMA Neurol. 2020 Aug 1;77(8):955-965
pubmed: 32391858
Neuroimage. 2012 Aug 15;62(2):774-81
pubmed: 22248573
Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):342-354
pubmed: 31612245
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Hum Brain Mapp. 2018 Feb;39(2):691-708
pubmed: 29105977
J Labelled Comp Radiopharm. 2021 Mar;64(3):109-119
pubmed: 33067819
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2178-2189
pubmed: 31264169
JAMA Neurol. 2020 Nov 1;77(11):1408-1419
pubmed: 33165511
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Arch Neurol. 1964 Apr;10:333-59
pubmed: 14107684
Alzheimers Dement. 2019 Apr;15(4):570-580
pubmed: 30639421
Neuroimage. 2009 Jun;46(2):486-99
pubmed: 19385016
Neuroimage. 2017 Nov 1;161:171-178
pubmed: 28756238
Neurobiol Aging. 2019 Sep;81:138-145
pubmed: 31280117
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2077-2089
pubmed: 31254035
Neurology. 1994 Nov;44(11):2015-9
pubmed: 7969952
Brain Commun. 2021 Aug 24;3(4):fcab190
pubmed: 34632382
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
Neuroimage. 2022 Dec 1;264:119763
pubmed: 36427751
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2866-2878
pubmed: 32291510
Brain. 2016 May;139(Pt 5):1539-50
pubmed: 26936940
J Nucl Med. 2017 Jun;58(6):975-981
pubmed: 28232614
Nat Rev Neurosci. 2018 Nov;19(11):687-700
pubmed: 30266970
J Alzheimers Dis. 2017;60(1):283-293
pubmed: 28800330
Ann Neurol. 2017 Oct;82(4):622-634
pubmed: 28980714
Nat Rev Neurol. 2018 Apr;14(4):225-236
pubmed: 29449700
J Cereb Blood Flow Metab. 2021 Nov;41(11):2957-2972
pubmed: 34044665
Parkinsonism Relat Disord. 2022 May;98:92-98
pubmed: 35533530
Brain Res Brain Res Rev. 2000 Aug;33(1):95-130
pubmed: 10967355
Neuropathology. 2006 Oct;26(5):475-83
pubmed: 17080728
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Brain. 2007 Jun;130(Pt 6):1566-76
pubmed: 17525140
J Med Chem. 2016 May 26;59(10):4778-89
pubmed: 27088900
Neuron. 2021 Jan 6;109(1):42-58.e8
pubmed: 33125873
J Neuropathol Exp Neurol. 1996 Jan;55(1):97-105
pubmed: 8558176
Alzheimers Res Ther. 2018 Jul 31;10(1):74
pubmed: 30064520
Eur J Nucl Med Mol Imaging. 2017 May;44(5):850-857
pubmed: 27966045
Neuroimage. 2009 Aug 15;47(2):618-27
pubmed: 19398016
Acta Neuropathol. 2020 Aug;140(2):99-119
pubmed: 32383020